Pfizer Seeks FDA Approval for Vaccine

A Record-Breaking Vaccine Development Process

On Friday, Pfizer (PFE) asked US health regulators to allow the use of its COVID-19 vaccine. This marks a significant milestone in the race to find a way to stop the virus which has taken over one million lives and caused economic upheaval around the world. Last week, Pfizer and its vaccine development partner BioNTech (BNTX) shared that their two-shot vaccine proved safe and 95% effective in a 44,000-person trial.

The FDA is expected to conduct the review process quickly given how impactful a COVID-19 vaccine would be. However, the health regulators have also emphasized that they will hold the vaccine to a high standard to ensure that it is safe for millions of people to receive.

Looking Ahead

Pfizer shared that distribution could begin as soon as mid-December, which would make this one of the fastest vaccine development efforts ever. Typically the process of researching, creating, and testing a vaccine takes at least 10 years. However, the stakes of finding a COVID-19 vaccine could not be higher, and researchers are rising to the challenge of finding a safe, effective shot in record time.

If and when the FDA approves the vaccine, there will be more hurdles to clear, from manufacturing and transporting shots to assuring the public that the shot is safe. It is possible that certain sectors of the population who are vulnerable to the virus, like healthcare workers and elderly citizens, would receive the vaccine first.

Other Developments in the Fight Against COVID-19

Health experts are also reviewing products for fighting COVID-19 developed by other companies. On Friday, the World Health Organization recommended against the use of Remdesivir, a drug for treating the virus developed by Gilead (GILD). Gilead has contested the claims and the FDA approved Remdesivir as a way to treat COVID-19 patients in October. Last week the FDA also granted emergency use authorization for baricitinib, a drug developed by Eli Lilly (LLY), used to help patients recover from COVID-19.

Moderna (MRNA) has also reported positive results from its COVID-19 vaccine trial. After the company finishes gathering safety-related data, it plans to seek FDA authorization in a matter of weeks.

Please understand that this information provided is general in nature and shouldn’t be construed as a recommendation or solicitation of any products offered by SoFi’s affiliates and subsidiaries. In addition, this information is by no means meant to provide investment or financial advice, nor is it intended to serve as the basis for any investment decision or recommendation to buy or sell any asset. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi. These links are provided for informational purposes and should not be viewed as an endorsement. No brands or products mentioned are affiliated with SoFi, nor do they endorse or sponsor this content.
Communication of SoFi Wealth LLC an SEC Registered Investment Advisor
SoFi isn’t recommending and is not affiliated with the brands or companies displayed. Brands displayed neither endorse or sponsor this article. Third party trademarks and service marks referenced are property of their respective owners.
SOSS112302